A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients
This Phase I clinical trial is studying the side effects and best dose of ABT-888 when given together with Temozolomide (chemotherapy) in treating patients with solid tumors, including metastatic melanoma (MM), BRCA deficient breast, ovarian, primary peritoneal, or fallopian tube cancer, and hepatocellular carcinoma (HCC).
Non-hematologic Malignancies|Metastatic Melanoma|Breast Cancer|Ovarian Cancer|Primary Peritoneal Cancer|Fallopian Tube Cancer|Hepatocellular Carcinoma
DRUG: ABT-888|DRUG: Temozolomide
Maximum Tolerated Dose, Duration of Study|Safety and Tolerability, Duration of Study|Pharmacokinetic Profile, Duration of Study
A Phase 1, multicenter, dose-escalation study evaluating the safety and tolerability of the PARP inhibitor ABT-888 in combination with Temozolomide (TMZ) in subjects with non-hematologic malignancies (NHM), including metastatic melanoma (MM), BRCA deficient breast, ovarian, primary peritoneal, or fallopian tube cancer, and hepatocellular carcinoma (HCC).